98%
921
2 minutes
20
Photodynamic Therapy (PDT) is an emerging method to treat colorectal cancers (CRC). Hypericin (HYP) is an effective mediator of PDT and the ABCG2 inhibitor, Febuxostat (FBX) could augment PDT. HT29 and HEK293 cells showed light dependant cytotoxic response to PDT in both 2D and 3D cell models. FBX co-treatment was not found to improve PDT cytotoxicity. Next, ABCG2 protein expression was observed in HT29 but not in HEK293 cells. However, ABCG2 gene expression analysis did not support protein expression results as ABCG2 gene expression results were found to be higher in HEK293 cells. Although HYP treatment was found to significantly reduce ABCG2 gene expression levels in both cell lines, FBX treatment partially restored ABCG2 gene expression. Our findings indicate that FBX co-treatment may not be suitable for augmenting HYP-mediated PDT in CRC but could potentially be useful for other applications.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s43630-024-00575-w | DOI Listing |
J Biochem Mol Toxicol
September 2025
Biochemistry Division, Chemistry Department, Faculty of Science, Tanta University, Tanta, Egypt.
Breast cancer is one of the most lethal cancers in women worldwide. Tamoxifen (TAM), a nonsteroidal antiestrogen, is a highly successful treatment for breast cancer. However, developed resistance to TAM can substantially impair chemotherapy efficacy, resulting in poor prognosis and cancer recurrence.
View Article and Find Full Text PDFFront Pharmacol
August 2025
The First Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine, Harbin, China.
Hyperuricemia (HUA) is a prevalent metabolic disorder driven by dysregulated purine metabolism and impaired urate excretion, and robust animal models are critical for elucidating its pathophysiology and guiding therapy development. This review systematically examines chemically induced, gene-edited, environmental, exercise and microbiota-based HUA models across rodents, poultry, primates, zebrafish and silkworms, highlighting each model's strengths and limitations in mimicking human uric acid handling. We discuss how these models have validated standard urate-lowering treatments-such as xanthine oxidase inhibitors and uricosurics-and uncovered emerging therapeutic targets, including the gut-NLRP3 inflammasome axis and SIRT1-mediated ABCG2 regulation.
View Article and Find Full Text PDFEur J Pharm Biopharm
September 2025
Research Center for Macromolecules and Biomaterials, National Institute for Materials Science, Namiki 1-1, Ibaraki 305-0044, Japan; Graduate School of Science and Technology, University of Tsukuba, Ibaraki 305-8577, Japan. Electronic address:
Chemotherapy is one of the most common strategies for treating colorectal cancer (CRC). However, acquired drug resistance (ADR) impairs the efficiency of chemotherapy. For CRC treatment, the long-term administration could affect cancer microenvironment and induce environment-mediated drug tolerance that contributes to ADR.
View Article and Find Full Text PDFPharmacogenet Genomics
October 2025
Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, Michigan, USA.
Irinotecan treatment is often complicated by gastrointestinal, hematological, and infusion-related toxicities, the latter of which typically presents as acute cholinergic syndrome (ACS). While genetic variation in UGT1A1 increases toxicity risk, fewer studies have investigated variation in other genes. This study aimed to assess the impact of variation in other genes involved in irinotecan pharmacokinetics with irinotecan-related toxicity.
View Article and Find Full Text PDFDrug Des Devel Ther
September 2025
School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, People's Republic of China.
Rivaroxaban is a direct oral anticoagulant (DOAC) that directly inhibits coagulation factor Xa and exerts its anticoagulant effects. Although rivaroxaban generally exhibits predictable pharmacokinetic (PK) and pharmacodynamic (PD) profiles, significant interindividual variability in therapeutic responses exists. Research on the role of genetic factors in the clinical variability of rivaroxaban is relatively new and extensive.
View Article and Find Full Text PDF